Perspective Therapeutics CATX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $91.26M+88.1% | $84.22M+102% | $64.17M+79.1% | $55.86M+90.3% | $48.52M+90.6% | ||
| $29.38M+2.8% | $30.23M+13.6% | $31.53M+35.3% | $30.77M+47.9% | $28.58M+40.9% | ||
| —— | $0— | $24.1M— | —— | —— | ||
| $120.63M+19.2% | $114.45M+23.9% | $119.79M+103% | $110.72M+121% | $101.18M+121% | ||
| $120.63M+19.2% | $114.45M+23.9% | $119.79M+103% | $110.72M+121% | $101.18M+121% | ||
| -$120.01M-20.4% | -$113.56M-25.0% | -$118.72M-106% | -$109.49M-125% | -$99.71M-126% | ||
| $7.93M-32.2% | $8.11M-22.8% | $9.15M+15.3% | $10.77M+137% | $11.69M+560% | ||
| $7.57M-41.4% | $9.14M-12.6% | $10.31M+32.6% | $11.93M+169% | $12.93M+680% | ||
| —— | -$104.43M-29.8% | -$108.41M-118% | -$97.56M-120% | -$86.78M-104% | ||
| -$111.13M-30.5% | -$103.12M-30.1% | -$105.8M-65.9% | -$94.95M-60.9% | -$85.17M-45.8% | ||
| —— | $514K+154% | $514K+108% | $514K+107% | -$490K+93.9% | ||
| -$1.40-12.0% | -$1.40-12.0% | -$1.50+3.2% | -$1.36+20.5% | -$1.25+35.2% | ||
| -$1.40-12.0% | -$1.40-12.0% | -$1.50+3.2% | -$1.36+20.5% | -$1.25+35.2% | ||
| 325.9M+18.9% | 294.7M+17.3% | 285.3M+33.6% | 281.6M+64.7% | 274.1M+107% | ||
| 325.9M+18.9% | 294.7M+17.3% | 285.3M+33.6% | 281.6M+64.7% | 274.1M+107% | ||
| $353K— | $376K— | —— | —— | —— | ||
| -$111.38M-30.8% | -$102.96M-29.8% | -$105.69M-108% | -$94.95M-101% | -$85.15M-80.5% | ||
| —— | $0— | $24.1M— | —— | —— | ||
| -$241K-1,368% | $165K+424% | $114K— | $3K— | $19K— | ||
| $0-100% | $1.4M— | $1.4M— | $1.4M— | $1.4M— | ||
| $618K-58.0% | $884K-39.2% | $1.08M-31.0% | $1.24M-15.6% | $1.47M-3.6% | ||
| -$120.01M-20.4% | -$113.56M-25.0% | -$118.72M-106% | -$109.49M-125% | -$99.71M-126% | ||
| -$116.37M-19.9% | -$110.31M-24.5% | -$115.77M-108% | -$106.65M-126% | -$97.03M-125% | ||
| -$116.37M-19.9% | -$110.31M-24.5% | -$115.77M-108% | -$106.65M-126% | -$97.03M-125% | ||
| -$120.01M-20.4% | -$113.56M-25.0% | -$118.72M-106% | -$109.49M-125% | -$99.71M-126% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Perspective Therapeutics's revenue?
- Perspective Therapeutics (CATX) generated $10.0M in revenue over the trailing twelve months, up 0.5% year over year.
- Is Perspective Therapeutics profitable?
- Perspective Therapeutics is not currently profitable: it reported a net loss of $111.1M over the trailing twelve months, a -218.4% net margin.
- What are Perspective Therapeutics's profit margins?
- Gross margin is 33.1% and operating margin is -292.7%, with a -218.4% net margin.
- What is Perspective Therapeutics's earnings per share?
- Perspective Therapeutics's diluted EPS over the trailing twelve months is $-1.40.
- Where does Perspective Therapeutics's income statement data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
